Brief: MEI Pharma Announces Update Of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone And In Combination With Venetoclax In Patients With Acute Myeloid Leukemia Or B-Cell Malignancies
23/05/2023 13:03
May 23 (Reuters) - MEI Pharma Inc MEIP.O :
* MEI PHARMA ANNOUNCES UPDATE OF ONGOING PHASE 1 STUDY
EVALUATING
ORAL CDK9 INHIBITOR VORUCICLIB ALONE AND IN COMBINATION WITH
VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR B-CELL
MALIGNANCIES
* MEI PHARMA ANNOUNCES UPDATE OF ONGOING PHASE 1 STUDY
EVALUATING
ORAL CDK9 INHIBITOR VORUCICLIB ALONE AND IN COMBINATION WITH
VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR B-CELL
MALIGNANCIES
* MEI PHARMA INC - VORUCICLIB ALONE OR IN COMBINATION WITH
VENETOCLAX WAS GENERALLY WELL TOLERATED WITH NO SIGNIFICANT
MYELOSUPPRESSION
Source text for Eikon: ID:nBw3b1pX9a
Further company coverage: MEIP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Lite Strategy
See all newsBrief: Lite Strategy Receives Governance Rights And Option To Buy Litvm Future Network Tokens
U.S. RESEARCH ROUNDUP- Equinix, KLA, WW Grainger
Brief: Lite Strategy Inc - On Nov 14, Board Approves Justin J. File As Permanent CEO - SEC Filing
Brief: Lite Strategy Reports First Quarter Fiscal Year 2026 Results Highlights Successful Launch Of $100M Litecoin Treasury Strategy And Movement Into Active Capital Market Operations
Brief: Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation To Active Capital Market Operations